TB500 Half Life: Human Studies Have Not Measured the Fragment

No published human study measured the half-life of the synthetic TB-500 fragment directly. The five half-lives rule can help estimate clearance once a half-life has been measured in the system being studied. Treat this as a hypothesis to confirm in your own assays, because molecular and measurement differences leave real uncertainty.

TL;DR:

The intravenous study measured full length thymosin beta 4, not TB 500; plasma half life ranged from 0.5 to 2.08 hours and rose with dose.

For a measured two day half life, first order math leaves about 3.1% of a single dose after five half lives, but this is illustrative.

Platelet contamination and sample handling can inflate measured concentrations, so record collection, anticoagulant, processing, and freezing details, then cross validate antibody results with mass spectrometry.

For repeated dosing, estimate washout from the final administration, and collect late samples only while concentrations remain above the assay’s quantification limit.

Neolabpeptides

Support Your Peptide Research

Explore research-grade peptides with third-party testing and Certificates of Analysis, supplied for laboratory research only.

Visit Neolabpeptides

How half-life math works and how to read the numbers
What the pharmacokinetic studies actually show
Why reported TB-500 half-lives differ
Practical implications for experimental design and sample handling
Why we treat the 2–3 day figure as a starting hypothesis
Research-grade material for your pharmacokinetic work
FAQ
Sources

How half-life math works and how to read the numbers

Biological half-life is the time it takes for the plasma concentration of a compound to fall by half. It is a property of the molecule, the route of administration and the biological system, so it only transfers between experiments when those three things match. A half-life is not a duration of effect. A compound can keep acting at the tissue level after plasma levels have dropped, and plasma can remain measurable after the signal of interest has faded.

The arithmetic is simple because elimination of most peptides is approximated as first-order: each half-life removes the same fraction of what remains, not the same absolute amount. With first-order elimination, the same fraction of the remaining amount is removed during each half-life. This is the basis of the rule of thumb that clearance can be estimated over several half-lives.

Here is how to apply the clearance math once a half-life has been measured. The examples assume a single administration and first-order elimination, and illustrate the arithmetic rather than measured TB-500 data.

Half-life of 2 days: after 2 days, 50% remains; after 4 days, 25%; after 6 days, 12.5%; after 8 days, 6.25%; after 10 days, about 3.1%. Roughly 97% is cleared at day 10.
For a different measured half-life: the amount remaining falls by the same fraction during each successive half-life. The clearance estimate depends on the measured half-life.
The range in practice: near-complete clearance of a single dose depends on the half-life measured in the system. A midpoint estimate is meaningful only when it is based on supported measurements.
Detection depends on your assay, not just the math: the amount remaining is only part of the picture. If your method can quantify very low concentrations, the compound may remain detectable beyond the point suggested by a simple clearance estimate. A less sensitive assay may lose the signal earlier.

A few points make these numbers easier to use. First, the calculation assumes the peptide behaves the same way across the whole time course. If it binds to tissue and redistributes, the plasma curve can show a fast early decline followed by a slower tail, and a single half-life describes only part of it. Second, the percentage remaining refers to the circulating pool, so a tissue-bound fraction may follow different kinetics. Third, the same peptide can have different apparent half-lives in different species, preparations and matrices, which is one reason cross-study comparisons should be made cautiously.

Repeated administration changes the picture. When a second dose is given before the first has cleared, the new dose adds to the residual amount, and the average level climbs until input and elimination balance. This is called accumulation, and it is a design consideration, not dosing advice. In a multi-dose experiment, the interval between administrations relative to the half-life determines how high the steady-state level sits, and the clearance clock restarts from the final dose. After repeated administrations, estimate washout from the final administration using a half-life measured in the relevant system.

The practical takeaway is to treat the 2–3 day figure as an input to planning, not as a fact about your own system. The math tells you where to look. Your own sampling tells you what is actually there.

$How half-life math works and how to read the numbers — overview diagram$

What the pharmacokinetic studies actually show

The strongest human pharmacokinetic data come from a randomized, placebo-controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteers. We rely on this paper because it is the primary clinical source for how the parent protein behaves in plasma, and it is the evidentiary anchor for any estimate of related fragments.

Several features of its design matter for interpretation:

Molecule measured: the study dosed full-length thymosin β4, the 43-amino-acid protein, not the TB-500 fragment.
Route: administration was intravenous, which bypasses absorption and gives the cleanest view of elimination, but does not reflect other routes.
Cohort structure: participants received ascending doses across single and multiple dose cohorts, covering 42–1,260 mg.
Dose behavior: the pharmacokinetics were reported as dose-proportional, and the half-life increased with increasing dose.
Population: healthy volunteers, so organ impairment, inflammation or tissue injury were not modeled.

The reported plasma half-life of full-length thymosin β4 in this human IV study ranged from about 0.5 to 2.08 hours, and it rose with dose. That is hours, not days, which is exactly why extrapolating to a multi-day figure for TB-500 requires care.

The gap between hours in the clinical study and a multi-day working estimate for TB-500 deserves a direct explanation, because a careful reader will notice it immediately. The IV study characterizes plasma clearance of the parent protein under a specific dosing regimen. A multi-day estimate for TB-500 would be an extrapolation. Tissue binding could affect how long material remains measurable, but the fragment’s persistence has not been established by a published human measurement cited here. We flag it as an estimate precisely because the supporting measurement for the fragment is not in the published human literature we cite here.

Why would a synthetic fragment differ from the full-length protein? Thymosin β4 is a 43-amino-acid protein of about 4.9 kDa that diffuses rapidly through tissues and binds actin, and those properties influence distribution and clearance. A fragment is smaller and has a different sequence and charge profile. Each of these can change how readily it is filtered, degraded by proteases, or sequestered in tissue. The direction of the effect is not guaranteed. A smaller molecule can be cleared faster by the kidney, yet a sequence that resists proteolysis or binds tissue more tightly can persist longer. That is why we describe the parent-protein data as informative, not decisive.

The study observed increasing half-life with increasing dose for the full-length protein. A half-life measured at one concentration may not describe another, so report the dose and concentration alongside any measured half-life.

Taken together, the evidence supports three statements with different levels of confidence. It firmly establishes that full-length thymosin β4 has a short plasma half-life after IV administration in healthy volunteers. It supports the idea that pharmacokinetics are dose-proportional with a half-life that grows with dose. It does not directly establish the half-life of the synthetic TB-500 fragment, which remains an extrapolated working figure. Keeping those three claims separate is the difference between a defensible methods section and a loose one.

Why reported TB-500 half-lives differ

If you have seen several different half-life numbers for TB-500 and thymosin β4, the disagreement is not necessarily a sign that someone is wrong. Much of it traces to how the molecule is measured. A literature review of circulating thymosin β4 measurement documents substantial intra- and inter-study variability and recommends standardized sample preparation and cross-validation with mass spectrometry.

Thymosin β4 is abundant inside platelets, so the way blood is drawn and processed can change the apparent concentration. Residual platelets in a plasma sample, or platelets activated after the draw, can release the peptide into the matrix and inflate the reading. The same sample processed two ways can therefore yield different numbers, and a half-life derived from those numbers inherits the error. Antibody-based assays add another layer, because their specificity for the full-length protein versus fragments determines what is actually being counted.

Biological factors also shape clearance, and each pushes the number in a predictable direction:

Route of administration: intravenous delivery produces an immediate peak and a clean elimination curve, while subcutaneous or other routes introduce an absorption phase that can lengthen the apparent half-life.
Proteolysis: peptidases in blood and tissue degrade peptides, and a sequence that resists cleavage will persist longer than one that does not.
Tissue binding: material sequestered in tissue is removed from plasma but may return slowly, creating a long terminal tail.
Molecular size: smaller peptides are more readily filtered by the kidney, which tends to shorten plasma half-life.
Dose: as the human IV study showed for the parent protein, higher doses were associated with longer half-lives.

Pro Tip: Record the matrix, anticoagulant, centrifugation steps and time from draw to freezing for every sample. When platelets are a possible contaminant, these details explain more of your variance than the assay itself.

The molecular difference between the fragment and the full-length protein is the main reason the parent-protein data cannot simply be carried over. A shorter sequence has a different susceptibility to proteases and a different affinity for the binding partners that hold the full-length protein in tissue. If the fragment resists degradation or binds tissue, its plasma and tissue persistence can exceed what the parent protein shows. If it is cleared more efficiently, it could fall below it. Without a direct measurement in the system you are studying, a specific half-life for the fragment should not be treated as established.

The practical consequence for anyone comparing published values is to ask four questions before trusting a number. What molecule was actually measured, the full-length protein or the fragment? By what method, and was it cross-validated? How were samples collected and processed? And at what dose and route? A half-life that cannot answer those questions should not anchor your design.

Practical implications for experimental design and sample handling

Translating a measured half-life into a sampling plan starts with matching your time points to the expected curve. These are experimental-design examples, not clinical dosing guidance.

Single-dose profiling: sample densely early to capture the distribution phase, then space time points across several measured half-lives. The observation period should be based on measurements in the system being studied.
Terminal phase: because the final few percent determine your detection window, include late points where your assay is still above its limit of quantification, and confirm the tail rather than assuming it.
Multi-dose accumulation studies: plan trough sampling just before each administration to track the rise toward steady state, and continue sampling after the last dose long enough to document washout based on the measured half-life.
Detection windows: the window is set by assay sensitivity as much as by half-life. A more sensitive mass spectrometry method will extend detectability beyond the point where a less sensitive immunoassay goes blind.
Replication: run the same time course in independent animals or preparations, because individual variation in clearance can be large relative to the differences you are trying to detect.

Accumulation changes the clearance math in a way worth restating for planning. Each repeated administration adds to the residual amount, so the time to clear depends on the dosing schedule. When administrations are close together relative to the measured half-life, the baseline may climb across the study. Plan washout from the final administration, not the first.

Handling affects measured stability as much as biology does. A peptide that degrades in the vial or in the sample before analysis will appear to have a shorter half-life than it really does. Our TB-500 storage guide covers lyophilized storage and reconstitution handling in detail, and following it reduces one source of artifactual variability. For background on how the fragment is described in our research materials, see our TB-500 research overview.

Everything we supply is for laboratory research only and is not approved for human or veterinary use, so confirm that your protocol has the institutional review and regulatory approvals it requires before you begin.

Why we treat the 2–3 day figure as a starting hypothesis

A specific half-life estimate for the synthetic fragment should not be published as a measured property without direct measurement. The best human data describe a different, larger molecule over hours, and the bridge to a multi-day figure rests on extrapolation and on the persistence researchers observe in practice. That is a defensible basis for planning a sampling schedule. It is not a defensible basis for a results table.

The more useful discipline is to separate what was measured from what was inferred, and to say so in the methods. Confirm identity and concentration with mass spectrometry instead of relying on one antibody assay, because the variability literature shows how much a single method can mislead. Document sample preparation thoroughly enough that another lab could reproduce your platelet handling, your freezing delay and your calibration. Replicate the time course before reporting a half-life.

I would also resist the temptation to equate half-life with biological activity. A short plasma half-life does not mean a short effect, and a long measurable tail does not mean a long effect. Report the pharmacokinetics as what they are and keep functional claims tied to functional endpoints. When you cite a figure, state the molecule, route, dose, matrix and method beside it. That habit does more for the credibility of a pharmacokinetic result than any single number does.

— Stephan

Research-grade material for your pharmacokinetic work

Reliable pharmacokinetics start with material you can trust, because an impure or mis-dosed peptide corrupts every downstream measurement. We supply research-grade peptides with third-party verification, including HPLC and mass spectrometry testing, and a Certificate of Analysis with each product, so you can confirm identity and purity before you design around a compound.

Neolabpeptides

Verify the Certificate of Analysis and the lab testing behind it before you purchase materials for any pharmacokinetic study. Our guide to peptide third-party testing explains what each test confirms and how to read the results. When you are ready to source material, these are good places to start:

Browse the Healing & Recovery category for research peptides used in regenerative and recovery studies.
Open the full shop to see our complete range of research peptides and lab supplies.
Order through your verified researcher account, with cold-chain shipping from US facilities and documentation included.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

FAQ

How long does TB-500 last in the body?

The half-life of the synthetic TB-500 fragment has not been established by a published human measurement cited here, so its clearance time cannot be reliably estimated from the available evidence. That figure is an extrapolation, since the human IV study measured the full-length protein, not the TB-500 fragment, so it should be confirmed in your own system.

Does TB-500 go bad?

Yes, peptides can degrade, and the main risks are heat, moisture and repeated handling after reconstitution. Lyophilized material is far more stable than reconstituted solution, and our storage guide outlines how to keep it intact. Degradation before analysis can also make a measured half-life look shorter than it is.

How many half-lives does it take to clear a peptide?

A clearance estimate depends on the measured half-life, and the point at which a compound becomes undetectable also depends on your assay’s sensitivity.

Sources

Differences in assay type, sample preparation and the molecule measured account for much of the spread. A literature review documents substantial variability in circulating thymosin β4 measurements and recommends standardized collection and mass spectrometry cross-validation. Dose, route and species add further variation.

TB500 Half Life: Human Studies Have Not Measured the Fragment

Table of Contents